Mitchell & Pahl Private Wealth LLC Purchases 4,881 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Mitchell & Pahl Private Wealth LLC boosted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 12.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 43,728 shares of the company’s stock after purchasing an additional 4,881 shares during the quarter. Mitchell & Pahl Private Wealth LLC’s holdings in Elanco Animal Health were worth $530,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its position in shares of Elanco Animal Health by 76.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock worth $147,747,000 after buying an additional 4,361,799 shares during the period. State Street Corp grew its position in shares of Elanco Animal Health by 2.6% during the 3rd quarter. State Street Corp now owns 9,912,693 shares of the company’s stock worth $145,617,000 after buying an additional 255,084 shares during the period. Geode Capital Management LLC grew its position in shares of Elanco Animal Health by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock worth $115,623,000 after buying an additional 65,303 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Elanco Animal Health by 6.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,385,467 shares of the company’s stock worth $93,803,000 after buying an additional 394,921 shares during the period. Finally, Wellington Management Group LLP grew its position in shares of Elanco Animal Health by 19.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock valued at $58,875,000 after purchasing an additional 646,522 shares during the period. 97.48% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ELAN has been the subject of several research analyst reports. Barclays boosted their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 8th. Stifel Nicolaus decreased their price objective on Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. UBS Group initiated coverage on Elanco Animal Health in a research report on Monday, December 9th. They issued a “buy” rating and a $18.00 price objective for the company. Leerink Partners initiated coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. Finally, Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $16.43.

Elanco Animal Health Trading Up 0.1 %

NYSE:ELAN opened at $12.04 on Wednesday. Elanco Animal Health Incorporated has a twelve month low of $11.11 and a twelve month high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average price of $12.43 and a two-hundred day moving average price of $13.32. The company has a market cap of $5.95 billion, a P/E ratio of 30.09, a price-to-earnings-growth ratio of 2.56 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the prior year, the firm posted $0.18 EPS. The business’s revenue was down 3.6% on a year-over-year basis. As a group, analysts expect that Elanco Animal Health Incorporated will post 0.92 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.